Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.
Clin Pharmacokinet
; 56(3): 305-310, 2017 03.
Article
em En
| MEDLINE
| ID: mdl-27461250
ABSTRACT
BACKGROUND:
For imatinib, a relationship between systemic exposure and clinical outcome has been suggested. Importantly, imatinib concentrations are not stable and decrease over time, for which several mechanisms have been suggested. In this study, we investigated if a decrease in alpha-1 acid glycoprotein (AGP) is the main cause of the lowering in imatinib exposure over time.METHODS:
We prospectively measured imatinib trough concentration (C min) values in 28 patients with gastrointestinal stromal tumours, at 1, 3 and 12 months after the start of imatinib treatment. At the same time points, AGP levels were measured.RESULTS:
Overall, imatinib C min and AGP levels were correlated (r 2 = 0.656; P < 0.001). However, AGP levels did not fluctuate significantly over time, nor did the change in AGP levels correlate with the change in the imatinib C min.CONCLUSION:
We showed that systemic AGP levels are not likely to be a key player in the decrease in systemic imatinib exposure over time. As long as intra-individual changes in imatinib exposure remain unexplained, researchers should standardize the sampling times for imatinib in order to be able to assess the clinical applicability of therapeutic drug monitoring.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Orosomucoide
/
Tumores do Estroma Gastrointestinal
/
Mesilato de Imatinib
/
Neoplasias Gastrointestinais
/
Antineoplásicos
Tipo de estudo:
Observational_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Pharmacokinet
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Holanda